Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-APOC3 long-term open-label extension in adults with mixed dyslipidemia
NL-OMON60060Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jul 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plozasiran in combined dyslipidaemia, sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jul 2024; status: completed.
02
Drugs
plozasiran
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on NL-OMON60060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60060.